Implications of plant glycans in the development of innovative vaccines

References

• Pulendran B, Oh JZ, Nakaya HI, et al. Immunity to viruses: learning from successful human vaccines. Immunol Rev. 2013;255:243–255.
   PubMed Web of Science ®Google Scholar
• Thomas S, Luxon BA. Vaccines based on structure-based design provide protection against infectious diseases. Expert Rev Vaccines. 2013;12:1301–1311.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines. 2011;10:523–537.
   PubMed Web of Science ®Google Scholar
• Mukherjee C, Mäkinen K, Savolainen J, et al. Chemistry and biology of oligovalent β-(1→2)-linked oligomannosides: new insights into carbohydrate-based adjuvants in immunotherapy. Chemistry. 2013;19:7961–7974.
   PubMed Web of Science ®Google Scholar
• Heidelberger M, Avery OT. The soluble specific substance of pneumococcus. J Exp Med. 1923;38:73–79.
   PubMedGoogle Scholar
• Dalziel M, Crispin M, Scanlan CN, et al. Emerging principles for the therapeutic exploitation of glycosylation. Science. 2014;343:1235681.
   PubMed Web of Science ®Google Scholar
• Liu CC, Ye XS. Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J. 2012;29:259–271.
   PubMed Web of Science ®Google Scholar
• Heimburg-Molinaro J, Lum M, Vijay G, et al. Cancer vaccines and carbohydrate epitopes. Vaccine. 2011;29:8802–8826.
   PubMed Web of Science ®Google Scholar
• Food and drugs administration (FDA). PneumoVax approval; [cited 2015 Aug 5]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM257088.pdf
   Google Scholar
• Aljunid S, Abuduxike G, Ahmed Z, et al. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. BMC Infect Dis. 2011;11:248.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214–222.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009;16:1810–1815.
   PubMed Web of Science ®Google Scholar
• Marcus LC, Froeschle JE, Hill DR, et al. Safety of Typhim Vi vaccine in a postmarketing observational study. J Travel Med. 2007;14:386–391.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–819.
   PubMedGoogle Scholar
• Deng L, Kasper DL, Krick TP, et al. Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus. J Biol Chem. 2000;275:7497–7504.
   PubMed Web of Science ®Google Scholar
• Coutinho A, Moller G. B cell mitogenic properties of thymus-independent antigens. Nature New Biol. 1973;245:12–14.
   PubMedGoogle Scholar
• Barrett DJ. Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants. Adv Pediatr. 1985;32:139–158.
   PubMedGoogle Scholar
• Sood RK, Fattom A. Capsular polysaccharide–protein conjugate vaccines and intravenous immunoglobulins. Expert Opin Investig Drugs. 1998;7:333–347.
   PubMedGoogle Scholar
• Lee CJ, Lee LH, Lu S, et al. Bacterial polysaccharides as vaccines – immunity and chemical characterization. Adv Exp Med Biol. 2001;491:453–471.
   PubMed Web of Science ®Google Scholar
• Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374:903–911.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global Immunization Data; 2014 [cited 2015 Aug 5]. Available from: http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf
   Google Scholar
• World Health Organization (WHO). Pneumonia fact sheet N°331; [cited 2015 Aug 5]. Available from: http://www.who.int/mediacentre/factsheets/fs331/en/
   Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–B63.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease: technical & clinical information; 2014 [cited 2015 Aug 5]. Available from: http://www.cdc.gov/meningococcal/clinical-info.html
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003; [cited 2015 Nov 25]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm
   Google Scholar
• Wernette CM, Frasch CE, Madore D, et al. Enzyme linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514–519.
   PubMedGoogle Scholar
• Wu DB, Chaiyakunapruk N, Chong HY, et al. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006–2014). Vaccine. 2015;33:1633–1658.
   PubMed Web of Science ®Google Scholar
• Jantan I, Ahmad W, Bukhari SN. Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front Plant Sci. 2015;6:655.
   PubMed Web of Science ®Google Scholar
• Mazmanian SK, Kasper DL. The love–hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol. 2006;6:849–858.
   PubMed Web of Science ®Google Scholar
• Guillén D, Moreno-Mendieta S, Pérez R, et al. Starch granules as a vehicle for the oral administration of immobilized antigens. Carbohydr Polym. 2014;112:210–215.
   PubMed Web of Science ®Google Scholar
• van de Wijdeven GG, Hirschberg HJ, Weyers W, et al. Phase 1 clinical study with Bioneedles, a delivery platform for biopharmaceuticals. Eur J Pharm Biopharm. 2015;89:126–133.
   PubMed Web of Science ®Google Scholar
• Amorij JP, Saluja V, Petersen AH, et al. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007;25:8707–8717.
   PubMed Web of Science ®Google Scholar
• Hütter J, Lepenies B. Carbohydrate-based vaccines: an overview. Methods Mol Biol. 2015;1331:1–10.
   PubMedGoogle Scholar
• Huang YL, Wu CY. Carbohydrate-based vaccines: challenges and opportunities. Expert Rev Vaccines. 2010;9:1257–1274.
   PubMed Web of Science ®Google Scholar
• Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin. 2011;7:313–321.
   PubMed Web of Science ®Google Scholar
• Shaaltiel Y, Gingis-Velitski S, Tzaban S, et al. Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher’s disease. Plant Biotechnol J. 2015;13:1033–1040.
   PubMed Web of Science ®Google Scholar
• Smith CM, Fry SC, Gough KC, et al. Recombinant plants provide a new approach to the production of bacterial polysaccharide for vaccines. PLoS One. 2014;9:e88144.
   PubMed Web of Science ®Google Scholar
• van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008;9:593–601.
   PubMed Web of Science ®Google Scholar
• Hudak JE, Bertozzi CR. Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol. 2014;21:16–37.
   PubMed Web of Science ®Google Scholar
• Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009;227:221–233.
   PubMed Web of Science ®Google Scholar
• Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.
   PubMed Web of Science ®Google Scholar
• Stephen AM. Other plant polysaccharides. In: Aspinall GO, editor. The polysaccharides. Vol. 2. New York (NY): Academic Press; 1983. p. 97–193.
   Google Scholar
• Cooper PD, Carter M. Anti-complementary action of polymorphic “solubility forms” of particulate inulin. Mol Immunol. 1986;23:895–901.
   PubMed Web of Science ®Google Scholar
• Cooper PD, Steele EJ. The adjuvanticity of gamma inulin. Immunol Cell Bio. 1988;66:345–352.
   PubMed Web of Science ®Google Scholar
• Cooper PD, Carter M. The anti-melanoma activity of inulin in mice. Mol Immunol. 1986;23:903–908.
   PubMed Web of Science ®Google Scholar
• Cooper PD, Steele EJ. Algammulin, a new vaccine adjuvant comprising γ inulin particles containing alum: preparation and in vitro properties. Vaccine. 1991;9:351–357.
   PubMed Web of Science ®Google Scholar
• Cooper PD, Turner R, McGovern J. Algammulin (γ inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice. Immunol Lett. 1991;27:131–134.
   PubMed Web of Science ®Google Scholar
• Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine. 2006;24(Suppl 2):26–29.
   Web of Science ®Google Scholar
• Cooper PD, Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2->1] poly(fructo-furanosyl) α-D-glucose polymers. Glycobiology. 2011;21:595–606.
   PubMed Web of Science ®Google Scholar
• Lobigs M, Pavy M, Hall RA, et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol. 2010;91:1407–1417.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012;30:5373–5381.
   PubMed Web of Science ®Google Scholar
• Saade F, Honda-Okubo Y, Trec S, et al. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013;31:1999–2007.
   PubMed Web of Science ®Google Scholar
• Bielefeldt-Ohmann H, Prow NA, Wang W, et al. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals. Vet Res. 2014;45:130.
   PubMed Web of Science ®Google Scholar
• Gordon D, Kelley P, Heinzel S, et al. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine. 2014;32:6469–6477.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Ong CH, Petrovsky N. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection. Vaccine. 2015;33:4892–4900.
   PubMed Web of Science ®Google Scholar
• Thiel S, Gadjeva M. Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Adv Exp Med Biol. 2009;653:58–73.
   PubMed Web of Science ®Google Scholar
• Sheng KC, Pouniotis DS, Wright MD, et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology. 2006;118:372–383.
   PubMed Web of Science ®Google Scholar
• Stambas J, Pietersz G, McKenzie I, et al. Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine. 2002;20:1068–1078.
   PubMed Web of Science ®Google Scholar
• Proudfoot O, Esparon S, Tang CK, et al. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung. BMC Infect Dis. 2015;15:101.
   PubMed Web of Science ®Google Scholar
• van de Wijdeven GG. Development and assessment of mini projectiles as drug carriers. J Control Release. 2002;85:145–162.
   PubMed Web of Science ®Google Scholar
• Hirschberg HJ, van de Wijdeven GG, Kraan H, et al. Bioneedles as alternative delivery system for hepatitis B vaccine. J Control Release. 2010;147:211–217.
   PubMed Web of Science ®Google Scholar
• Soema PC, Willems GJ, van Twillert K, et al. Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses. PLoS One. 2014;9:e92806.
   PubMed Web of Science ®Google Scholar
• Kraan H, Ploemen I, van de Wijdeven G, et al. Alternative delivery of a thermostable inactivated polio vaccine. Vaccine. 2015;33:2030–2037.
   PubMed Web of Science ®Google Scholar
• Christensen D, Lindenstrøm T, van de Wijdeven G, et al. Syringe free vaccination with CAF01 adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. PLoS One. 2010;5:e15043.
   PubMed Web of Science ®Google Scholar
• Hirschberg HJ, van de Wijdeven GG, Kelder AB, et al. Bioneedles as vaccine carriers. Vaccine. 2008;26:2389–2397.
   PubMed Web of Science ®Google Scholar
• Bolam DN, Ciruela A, McQueen-Mason S, et al. Pseudomonas cellulose-binding domains mediate their effects by increasing enzyme substrate proximity. Biochem J. 1998;331:775–781.
   PubMed Web of Science ®Google Scholar
• Rodriguez Sanoja R, Morlon-Guyot J, Jore J, et al. Comparative characterization of complete and truncated forms of Lactobacillus amylovorus alpha-amylase and role of the C-terminal direct repeats in raw-starch binding. Appl Environ Microbiol. 2000;66:3350–3356.
   PubMed Web of Science ®Google Scholar
• Guillén D, Moreno-Mendieta S, Aguilera P, et al. The starch-binding domain as a tool for recombinant protein purification. Appl Microbiol Biotechnol. 2013;97:4141–4148.
   PubMed Web of Science ®Google Scholar
• Moreno-Mendieta SA, Guillén D, Espitia C, et al. A novel antigen-carrier system: the Mycobacterium tuberculosis Acr protein carried by raw starch microparticles. Int J Pharm. 2014;474:241–248.
   PubMed Web of Science ®Google Scholar
• Dauvillée D, Delhaye S, Gruyer S, et al. Engineering the chloroplast targeted malarial vaccine antigens in Chlamydomonas starch granules. PLoS One. 2010;5:e15424.
   PubMed Web of Science ®Google Scholar
• Hayden CA, Fischer ME, Andrews BL, et al. Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses. Vaccine. 2015;33:2881–2886.
   PubMed Web of Science ®Google Scholar
• Streatfield SJ, Lane JR, Brooks CA, et al. Corn as a production system for human and animal vaccines. Vaccine. 2003;21:812–815.
   PubMed Web of Science ®Google Scholar
• Takaiwa F, Wakasa Y, Takagi H, et al. Rice seed for delivery of vaccines to gut mucosal immune tissues. Plant Biotechnol J. 2015;13:1041–1055.
   PubMed Web of Science ®Google Scholar
• Moravec T, Schmidt MA, Herman EM, et al. Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. Vaccine. 2007;25:1647–1657.
   PubMed Web of Science ®Google Scholar
• Hudson LC, Garg R, Bost KL, et al. Soybean seeds: a practical host for the production of functional subunit vaccines. Biomed Res Int. 2014;2014:340804.
   PubMed Web of Science ®Google Scholar
• Hevey R, Ling CC. Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies. Future Med Chem. 2012;4:545–584.
   PubMed Web of Science ®Google Scholar
• Anish C, Schumann B, Pereira CL, et al. Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol. 2014;21:38–50.
   PubMed Web of Science ®Google Scholar
• Carson TF, Maclay WD. The acetylation of polyuronides with formamides as a dispersing agent. J Am Chem Soc. 1946;68:1015–1017.
   PubMed Web of Science ®Google Scholar
• Szewczyk B, Taylor A. Immunochemical properties of Vi antigen from Salmonella typhi Ty2: presence of two antigenic determinants. Infect Immun. 1980;29:539–544.
   PubMed Web of Science ®Google Scholar
• Szu SC, Bystricky S, Hinojosa-Ahumada M, et al. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1–>4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever. Infect Immun. 1994;62(12):5545–5549.
   PubMed Web of Science ®Google Scholar
• Landy M. Studies in Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am J Hyg. 1954;60:52–62.
   PubMed Web of Science ®Google Scholar
• Kossaczka Z, Bystricky S, Bryla DA, et al. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun. 1997;65:2088–2093.
   PubMed Web of Science ®Google Scholar
• Szu SC, Lin KF, Hunt S, et al. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine. Vaccine. 2014;32:2618–2622.
   PubMed Web of Science ®Google Scholar
• Bock R. Engineering chloroplasts for high-level foreign protein expression. Methods Mol Biol. 2014;1132:93–106.
   PubMedGoogle Scholar
• Salazar-González JA, Bañuelos-Hernández B, Rosales-Mendoza S. Current status of viral expression systems in plants and perspectives for oral vaccines development. Plant Mol Biol. 2015;87:203–217.
   PubMed Web of Science ®Google Scholar
• Gleba YY, Tusé D, Giritch A. Plant viral vectors for delivery by Agrobacterium. Curr Top Microbiol Immunol. 2014;375:155–192.
   PubMed Web of Science ®Google Scholar
• Reski R, Parsons J, Decker EL. Moss-made pharmaceuticals: from bench to bedside. Plant Biotechnol J. 2015;13:1191–1198.
   PubMed Web of Science ®Google Scholar
• Wakasa Y, Takagi H, Watanabe N, et al. Concentrated protein body product derived from rice endosperm as an oral tolerogen for allergen-specific immunotherapy–a new mucosal vaccine formulation against Japanese cedar pollen allergy. PLoS One. 2015;10:e0120209.
   PubMed Web of Science ®Google Scholar
• Govea-Alonso DO, Cardineau GA, Rosales-Mendoza S. Principles of plant-based vaccines. In: Rosales-Mendoza S, editor. Genetically engineered plants as a source of vaccines against wide spread diseases - an integrated view. New York (NY): Springer Science Business Media; 2014. p. 1–14.
   Google Scholar
• Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J. 2007;5:579–590.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53.
   PubMed Web of Science ®Google Scholar
• Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402–2409.
   PubMed Web of Science ®Google Scholar
• McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ. 2014;349:g5488.
   PubMed Web of Science ®Google Scholar
• Bendandi M, Marillonnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol. 2010;21(12):2420–2427.
   Google Scholar
• Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol. 2014;154:164–177.
   PubMed Web of Science ®Google Scholar
• Jin C, Altmann F, Strasser R, et al. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology. 2008;18:235–241.
   PubMed Web of Science ®Google Scholar
• Ward BJ, Landry N, Trépanier S, et al. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine. 2014;32:6098–6106.
   PubMed Web of Science ®Google Scholar
• Strasser R, Stadlmann J, Schähs M, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J. 2008;6:392–402.
   PubMed Web of Science ®Google Scholar
• Castilho A, Gattinger P, Grass J, et al. N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans. Glycobiology. 2011;21:813–823.
   PubMed Web of Science ®Google Scholar
• Schähs M, Strasser R, Stadlmann J, et al. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J. 2007;5:657–663.
   PubMed Web of Science ®Google Scholar
• Castilho A, Neumann L, Daskalova S, et al. Engineering of sialylated mucin-type O-glycosylation in plants. J Biol Chem. 2012;287:36518–36526.
   PubMed Web of Science ®Google Scholar
• Hohe A, Reski R. Optimisation of a bioreactor culture of the moss Physcomitrella patens for mass production of protoplasts. Plant Sci. 2002;163:69–74.
   Web of Science ®Google Scholar
• Reski R, Abel WO. Induction of budding on chloronemata and caulonemata of the moss, Physcomitrella patens, using isopentenyladenine. Planta. 1985;165:354–358.
   PubMed Web of Science ®Google Scholar
• Lucumi A, Posten C, Pons MN. Image analysis supported moss cell disruption in photo-bioreactors. Plant Biol. 2005;7:276–282.
   PubMed Web of Science ®Google Scholar
• Lucumi A, Posten C. Establishment of long-term perfusion cultures of recombinant moss in a pilot tubular photobioreactor. Process Biochem. 2006;41:2180–2187.
   Web of Science ®Google Scholar
• Cerff M, Posten C. Enhancing the growth of Physcomitrella patens by combination of monochromatic red and blue light – a kinetic study. Biotechnol J. 2012;7:527–536.
   PubMed Web of Science ®Google Scholar
• Schween G, Egener T, Fritzkowsky D, et al. Large-scale analysis of 73,329 Physcomitrella plants transformed with different gene disruption libraries: production parameters and mutant phenotypes. Plant Biol. 2005;7:228–237.
   PubMed Web of Science ®Google Scholar
• Schaefer DG, Zrÿd J, Knight CD, et al. Stable transformation of the moss Physcomitrella patens. Mol Gen Genet. 1991;226:418–424.
   PubMedGoogle Scholar
• Hohe A, Egener T, Lucht JM, et al. An improved and highly standardised transformation procedure allows efficient production of single and multiple targeted gene knockouts in a moss, Physcomitrella patens. Curr Genet. 2004;44:339–347.
   PubMed Web of Science ®Google Scholar
• Koprivova A, Stemmer C, Altmann F, et al. Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol J. 2004;2:517–523.
   PubMed Web of Science ®Google Scholar
• Parsons J, Altmann F, Arrenberg CK, et al. Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants. Plant Biotechnol J. 2012;10:851–861.
   PubMed Web of Science ®Google Scholar
• Huether CM, Lienhart O, Baur A, et al. Glyco-engineering of moss lacking plant-specific sugar residues. Plant Biol. 2005;7:292–299.
   PubMed Web of Science ®Google Scholar
• Parsons J, Altmann F, Graf M, et al. A gene responsible for prolyl-hydroxylation of moss-produced recombinant human erythropoietin. Sci Rep. 2013;3:3019.
   PubMed Web of Science ®Google Scholar
• Büttner-Mainik A, Parsons A, Jérome H, et al. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol J. 2011;9:373–383.
   PubMed Web of Science ®Google Scholar
• Orellana-Escobedo L, Rosales-Mendoza S, Romero-Maldonado A, et al. An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice. Plant Cell Rep. 2014;34:425–433.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Orellana-Escobedo L, Romero-Maldonado A, et al. The potential of Physcomitrella patens as a platform for the production of plant-based vaccines. Expert Rev Vaccines. 2014;13:203–212.
   PubMed Web of Science ®Google Scholar
• Debolt S, Estevez JM. Current challenges in plant cell walls: editorial overview. Front Plant Sci. 2012;3:232.
   PubMed Web of Science ®Google Scholar
• Cosgrove DJ, Jarvis MC. Comparative structure and biomechanics of plant primary and secondary cell walls. Front Plant Sci. 2012;3:204.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Bushoven JT. The cellulose synthase (CESA) gene superfamily of the moss Physcomitrella patens. Plant Mol Biol. 2007;63:207–219.
   PubMed Web of Science ®Google Scholar
• Moller I, Sørensen I, Bernal AJ, et al. High-throughput mapping of cell-wall polymers within and between plants using novel microarrays. Plant J. 2007;50:1118–1128.
   PubMed Web of Science ®Google Scholar
• Arrecubieta C, Garcia E, Lopez R. Demonstration of UDP-glucose dehydrogenase activity in cell extracts of Escherichia coli expressing the pneumococcal cap3A gene required for the synthesis of type 3 capsular polysaccharide. J Bacteriol. 1996;178:2971–2974.
   PubMed Web of Science ®Google Scholar
• Jennings H. Capsular polysaccharides as human vaccine. Adv Carbo Chem. 1983;41:155–208.
   PubMed Web of Science ®Google Scholar
• Kunze R, Frommer WB, Flugge UI. Metabolic engineering of plants: the role of membrane transport. Metab Eng. 2002;4:57–66.
   PubMed Web of Science ®Google Scholar
• Sharples SC, Fry SC. Radioisotope ratios discriminate between competing pathways of cell wall polysaccharide and RNA biosynthesis in living plant cells. Plant J. 2007;52:252–262.
   PubMed Web of Science ®Google Scholar
• Wacker M, Feldman MF, Callewaert N, et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc Natl Acad Sci USA. 2006;103:7088–7093.
   PubMed Web of Science ®Google Scholar
• Kowarik M, Young NM, Numao S, et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO Journal. 2006;25:1957–1966.
   PubMed Web of Science ®Google Scholar
• Iwashkiw JA, Fentabil MA, Faridmoayer A, et al. Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis. Microb Cell Fact. 2012;11:13.
   PubMed Web of Science ®Google Scholar
• Cuccui J, Thomas RM, Moule MG, et al. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol. 2013;3:130002.
   PubMed Web of Science ®Google Scholar
• Ihssen J, Kowarik M, Dilettoso S, et al. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 2010;9:61.
   PubMed Web of Science ®Google Scholar
• Wetter M, Kowarik M, Steffen M, et al. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj J. 2013;30:511–522.
   PubMed Web of Science ®Google Scholar
• Kämpf MM, Braun M, Sirena D, et al. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation. Microb Cell Fact. 2015;14:12.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Tello-Olea MA. Carrot cells: a pioneering platform for biopharmaceuticals production. Mol Biotechnol. 2015;57:219–232.
   PubMed Web of Science ®Google Scholar
• Ma JK, Drossard J, Lewis D, et al. Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J. 2015;13:1106–1120.
   PubMed Web of Science ®Google Scholar
• Sack M, Rademacher T, Spiegel H, et al. From gene to harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants. Plant Biotechnol J. 2015;13:1094–1105.
   PubMed Web of Science ®Google Scholar
• Mohagheghpour N, Dawson M, Hobbs P, et al. Glucans as immunological adjuvants. Adv Exp Med Biol. 1995;383:13–22.
   PubMedGoogle Scholar
• Huang H, Ostroff GR, Lee CK, et al. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. MBio. 2010;1:e00164–10.
   PubMed Web of Science ®Google Scholar
• Kaistha J, Sokhey J, Singh S, et al. Adjuvant effect of DEAE-dextran and tetanus toxoid on whole cell heat inactivated phenol preserved typhoid vaccine. Indian J Pathol Microbiol. 1996;39:287–292.
   PubMedGoogle Scholar
• Bachelder EM, Beaudette TT, Broaders KE, et al. In vitro analysis of acetylated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm. 2010;7:826–835.
   PubMed Web of Science ®Google Scholar
• Popov SV, Ovodov YS. Polypotency of the immunomodulatory effect of pectins. Biochemistry (Mosc). 2013;78:823–835.
   PubMed Web of Science ®Google Scholar